A phase 2 trial evaluating the effect of Everolimus alternating with Sunitinib on progression-free survival in patients with advanced renal cell carcinoma

Trial Profile

A phase 2 trial evaluating the effect of Everolimus alternating with Sunitinib on progression-free survival in patients with advanced renal cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Sunitinib
  • Indications Renal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms EVERSUN
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 11 Jun 2015 Status changed from discontinued to completed as per Australian New Zealand Clinical Trials Registry.
    • 24 Apr 2014 Status changed from active, no longer recruiting to discontinued.
    • 01 Feb 2014 Primary endpoint 'Progression-free-survival-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top